Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Genomic sequencing to find AML-causing mutations

Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK

Genomic sequencing to find AML-causing mutations ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )

The latest in multiple myeloma: a European and US perspective

Prof Paul Richardson and Prof Marivi Mateos

The latest in multiple myeloma: a European and US perspective ( Prof Paul Richardson and Prof Marivi Mateos )

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid...

Prof Susan Branford - Adelaide University Adelaide, Australia

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia ( Prof Susan Branford - Adelaide University Adelaide, Australia )

Advances in the treatment and management of CLL

Prof Clemens Wendtner and Prof Peter Hillmen

Advances in the treatment and management of CLL ( Prof Clemens Wendtner and Prof Peter Hillmen )

Transplantation combined with novel agents optimal treatment for multiple...

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

Transplantation combined with novel agents optimal treatment for multiple myeloma ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

Monoclonal antibodies and multiple myeloma

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

Monoclonal antibodies and multiple myeloma ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

New definition for multiple myeloma improves patient outcomes

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

New definition for multiple myeloma improves patient outcomes ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

Factors influencing response to blinatumomab in relapsed/refractory ALL

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Factors influencing response to blinatumomab in relapsed/refractory ALL ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Evidence for kinase inhibitor activity in acute myeloid leukaemia

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

Evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Targeted combination therapy with potential to eliminate relapsed chronic...

Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

New targeted combination therapy with potential to eliminate relapsed chronic...

Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia ( Dr Andrew Roberts - Royal Melbourne Hospital, Melbourne, Australia )

More from ecancer